Selinexor and azacitidine after stem cell transplant for NK/T-cell lymphoma
Part of Cancer clinical trials.
This trial tests two drugs—selinexor and azacitidine—given as a maintenance therapy after a donor stem cell transplant for NK/T-cell lymphoma. The goal is to help prevent the lymphoma from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with NK/T-cell lymphoma.
- You have already received a donor stem cell transplant and your body is fully using the donor's blood cells (based on a chimerism test).
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your blood counts are stable: a neutrophil count above 1.0 and a platelet count above 75.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This trial tests a combination of chemotherapy drugs given before a donor stem cell transplant for people with NK/T-cell lymphoma. The goal is to see if this preconditioning helps the transplant work better.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This trial tests a combination of three drugs—selinexor, an anti-PD-1 antibody (immune therapy), and golidocitinib—for people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like MDS, AML, or CMML, especially those who have leftover leukemia cells before a stem cell transplant. The goal is to see if this treatment can improve outcomes.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.